Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04938635
Other study ID # VIT-2763-THAL-203
Secondary ID 2021-001639-23
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 20, 2021
Est. completion date July 2023

Study information

Verified date March 2022
Source Vifor Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.


Description:

All patients giving written informed consent will undergo a 12-week screening period to determine eligibility for study entry. At Day 1, patients who meet the eligibility requirements will be randomized in a double-blind manner to 1 of 4 treatment groups: VIT-2763 60 mg (once daily), 60 mg (twice daily), or 120 mg (twice daily) or placebo. The randomisation will be stratified (balanced allocation across treatment groups) according to β0/β0 genotype (yes/no). The duration of the treatment with VIT-2763 or placebo is 24 weeks, after which patients will undergo a 12-week post-treatment follow-up period.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2023
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Body weight =40.0 kg and =100 kg at screening - Documented diagnosis of beta-thalassemia or Hb E/beta-thalassemia - Red blood cell (RBC) transfusion dependence, defined as at least 6 RBC units in the 24 weeks prior to randomization and no transfusion-free period for =35 days during that period - Ability to understand the requirements of the study and provide written informed consent Exclusion Criteria: - Documented diagnosis of Hb S/beta-thalassemia, alpha-thalassemia, or delta beta (dß)-thalassemia, or hereditary persistence of foetal Hb. - History of partial or total splenectomy within 4 months prior to screening. - History of myocardial iron overload - Chronic liver disease or history of liver cirrhosis - Clinically relevant renal disease - History or clinically important finding of cardiac disorders - History of clinically significant lung disease - Uncontrolled hypertension (> Grade 1 according to NCI CTCAE current version) - Unable to take and absorb oral medications. - Pregnancy or breastfeeding - History of drug or alcohol abuse within 2 years prior to screening - History or concomitant solid tumors and/or hematological malignancies unless resolved in the =5 past years.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VIT-2763 60 mg QD
Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
VIT-2763 60 mg BID
Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
VIT-2763 120 mg BID
Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
Placebo
Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.

Locations

Country Name City State
Bulgaria Investigational site #802 Plovdiv
Bulgaria Investigational site #801 Sofia
Bulgaria Investigational site #804 Stara Zagora
Israel Investigator Site 404 Jerusalem
Israel Investigator Site 406 Petah tikva
Israel Investigator Site 405 Safed
United States Investigator site #710 Whittier California

Sponsors (2)

Lead Sponsor Collaborator
Vifor (International) Inc. Labcorp Drug Development Inc

Countries where clinical trial is conducted

United States,  Bulgaria,  Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients achieving =33% reduction of RBC transfusions from baseline and a reduction of =2 units assessed consecutively from Week 13 to Week 24 compared to the baseline transfusion Week 13 to Week 24 comparing to Baseline (Day -83 to Day 1)
Secondary Change from baseline in RBC transfusions over Weeks 13 to 24 compared to the baseline RBC transfusion burden derived using the last 12 weeks prior to randomization. Week 13 to Week 24 comparing to Baseline (Day -83 to Day 1)
Secondary Proportion of patients achieving =50% reduction of RBC transfusions and =2 units assessed over any consecutive 12-week interval from Week 1 to 24. Any consecutive 12-week interval from Week 1 to Week 24 comparing to Baseline (Day -83 to Day 1)
Secondary Proportion of patients achieving =33% reduction of RBC transfusions and =2 units assessed over any consecutive 12-week interval from Week 1 to 24. Any consecutive 12-week interval from Week 1 to Week 24 comparing to Baseline (Day -83 to Day 1)
Secondary Mean change from baseline in Quality of Life (QoL) total score Transfusion-dependent QoL Questionnaire (TranQuol): a disease-specific, validated, QoL measure developed for thalassemia patients. The adult version includes 36 questions grouped into 5 domains: physical health, emotional health, sexual health, family functioning, and school/career functioning. The total score ranges from 0 (worst) to 100 (best). Week 15 and Week 24 comparing to Baseline (Day 1)
See also
  Status Clinical Trial Phase
Completed NCT00069862 - Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia Phase 1/Phase 2
Completed NCT00733811 - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Phase 4
Completed NCT05506358 - Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada N/A
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Completed NCT06239389 - Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study. Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT03271541 - A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia Phase 2
Terminated NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia Phase 1
Completed NCT01206075 - Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major N/A
Recruiting NCT05567458 - A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT03961828 - Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus Phase 4
Recruiting NCT06065189 - Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major Early Phase 1
Recruiting NCT04143724 - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia Phase 2
Terminated NCT03381833 - A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia Phase 2
Not yet recruiting NCT01996683 - Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml) N/A
Completed NCT02268409 - ACE-536 Extension Study - Beta Thalassemia Phase 2
Active, not recruiting NCT01016093 - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients Phase 2/Phase 3
Completed NCT01039636 - Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload Phase 1
Withdrawn NCT01927913 - Treatment of Iron Overload Requiring Chelation Therapy Phase 2